GleamWall
中文EN

ONCO Onconetix, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1782107 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-51.3%
TTM net income YoY76.9%
TTM EPS YoY216.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.4%
Operating margin-2,525.0%
Net margin-1,578.8%
FCF margin—
EBITDA margin-2,522.7%

Returns

ROE-105.2%
ROA-57.4%
ROIC (approx.)-195.9%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets18.0%
Debt / equity0.00x
Current ratio2.21x
Interest coverage-52.44x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$102,884$17,120$21,457$303,596$303,651$106,494$101,630$711,976
Cost of revenue$24,718$12,817$23,112$55,912$34,757$35,991$55,798$52,008
Gross profit$78,166$4,303-$1,655$247,684$268,894$70,503$45,832$659,968
R&D expense——————$24,455-$290
SG&A expense$1.48M$2.25M$2.04M$1.50M$2.34M$1.52M$1.67M$2.63M
Operating income-$1.41M-$2.73M-$10.23M-$1.28M-$2.07M-$1.94M-$12.57M-$29.15M
Interest expense$3,246$4,389$2,244$4,247$300,069$223,097$223,592$339,188
Pretax income-$31.63M-$2.87M-$4.21M$5.67M-$8.78M-$2.37M-$8.55M-$30.36M
Income tax———————-$917,997
Net income-$31.63M-$2.87M-$4.21M$5.67M-$8.78M-$2.37M-$8.55M-$29.44M
EBITDA-$1.40M-$2.73M-$10.22M-$1.28M-$2.07M-$1.93M-$12.57M-$29.03M
EPS (basic)-76.01-1.28-6.71—-3,124.76-237.91-227.25—
EPS (diluted)-76.01-1.28-6.71—-3,124.76-237.91-227.25—
Weighted avg. shares (diluted)416,1172.24M628,528—2,81111,35342,755—
Banking
Deposits———————$3.50M
Balance sheet
Cash & equivalents$2.74M$5.94M$3.72M$5.22M$836,556$283,515$1.58M$646,500
Receivables$103,421$2,351$43,725$296,866$2,552$12,156$16,293$25,717
Inventory$192,644$210,448$137,642$149,961$151,556$153,072$155,660$64,079
Current assets$5.94M$6.52M$4.33M$6.07M$1.30M$930,531$2.42M$950,267
PP&E, net$25,297$28,655$31,533$37,085$40,388$43,809$55,805$62,896
Goodwill$9.33M$9.62M$10.20M$18.55M$18.18M$18.12M$16.21M$18.55M
Total assets$15.55M$16.43M$14.83M$24.93M$19.68M$19.12M$18.78M$28.18M
Current liabilities$4.03M$2.94M$3.07M$9.14M$16.30M$12.69M$14.04M$18.29M
Total liabilities$4.04M$2.96M$3.08M$9.16M$16.30M$12.77M$14.26M$18.57M
Shareholders' equity-$17.29M$13.47M$11.75M$15.76M$3.37M$5.91M$3.99M$8.54M
Shares outstanding—3.79M2.76M31,1981.56M1.01M36.76M138,270
Cash flow statement
Operating cash flow-$1.72M-$1.92M-$2.12M-$3.09M-$3.18M-$1.41M-$2.00M-$917,647
Capital expenditure———————$3,874
Free cash flow———————-$921,521
Investing cash flow———————-$3,874
Financing cash flow$1.08M$4.17M$631,788$6.55M$4.29M$744,574$2.87M$1.30M
Depreciation & amortization$2,552$2,632$5,398$3,336$3,387$3,699$4,748$119,299
Stock-based compensation$0$7,359$22,305$4,234$9,795$30,982$29,256$340,425

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.